Clinical Trial Update: A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects [Phase 1, Phase 2]

View source ↗

Summary

This document notes the completion of a single ascending dose study of BMS-791325 in subjects with chronic hepatitis C in Phase 1/2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-791325

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C | Phase 1, Phase 2 | Status: COMPLETED